vidarabine - Profile

What are the generic sources for vidarabine and what is the scope of patent protection?

Vidarabine is the generic ingredient in one branded drug marketed by Parkedale and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for vidarabine

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for vidarabine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Parkedale	VIRA-A	vidarabine	INJECTABLE;INJECTION	050523-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Parkedale	VIRA-A	vidarabine	OINTMENT;OPHTHALMIC	050486-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Vidarabine: An Antiviral Drug Investment Analysis

Last updated: February 19, 2026

Vidarabine, a synthetic nucleoside analog, presents a niche but established market within antiviral therapeutics. Its primary utility targets herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections, including ophthalmic and dermatological manifestations. While newer, more targeted antivirals have emerged, vidarabine retains a position due to its established efficacy and, in certain formulations, cost-effectiveness.

What is Vidarabine's Current Market Position?

Vidarabine's market penetration is concentrated in specific indications where its antiviral activity against DNA viruses is most effective. Its historical significance lies in its pioneering role in treating severe herpes infections before the advent of more advanced therapies.

Key Therapeutic Areas

• Ophthalmic Herpes Simplex Keratitis: Vidarabine is FDA-approved for treating herpes simplex virus keratitis, an infection of the cornea that can lead to vision loss. This application remains a core market segment.
• Herpes Zoster (Shingles): It has been used for the treatment of herpes zoster, particularly in immunocompromised patients, though its use has largely been superseded by acyclovir and its analogs for systemic treatment.
• Herpes Simplex Encephalitis: Historically, vidarabine was a treatment option for this severe neurological complication of HSV, but it has been largely replaced by intravenous acyclovir due to better penetration of the central nervous system and improved safety profiles.

Competitive Landscape

The antiviral market is highly competitive. Vidarabine faces competition from:

• Acyclovir and Valacyclovir: These are the most widely prescribed drugs for HSV and VZV infections. They exhibit superior oral bioavailability and improved safety profiles compared to vidarabine.
• Famciclovir and Penciclovir: These are also potent antiviral agents used for similar indications.
• Trifluridine: Used topically for ocular herpes infections, it competes directly with ophthalmic vidarabine.

What are the Key Patents and Exclusivity Periods for Vidarabine?

Vidarabine's patent landscape is largely characterized by expired foundational patents. The original patents covering its synthesis and therapeutic use have long since lapsed, allowing for generic competition.

Original Patent Expiries

• The initial patents for vidarabine, primarily held by Parke-Davis (a division of Warner-Lambert, later acquired by Pfizer), expired in the late 1980s and early 1990s.
• This has led to the widespread availability of generic formulations of vidarabine, impacting pricing and market share for branded products.

Current Exclusivity and New Development

• Orphan Drug Exclusivity: There are no current indications for vidarabine that benefit from Orphan Drug Exclusivity in major markets like the U.S. or EU.
• New Formulations or Indications: Any potential for extended exclusivity would likely stem from novel formulations (e.g., improved delivery systems for ophthalmic use) or the discovery of new therapeutic applications. However, significant R&D investment in such areas for vidarabine appears limited given the maturity of the compound and the availability of more advanced alternatives.
• Process Patents: While composition of matter patents have expired, there might be some limited protection for novel manufacturing processes. However, these typically offer less robust market exclusivity than primary drug patents.

What is the Regulatory Status and Market Access for Vidarabine?

Vidarabine has received regulatory approval in key pharmaceutical markets, but its current regulatory standing reflects its established, rather than innovative, status.

United States

• FDA Approval: Vidarabine (Vira-A) was approved by the U.S. Food and Drug Administration (FDA) for ophthalmic use.
• Generics: Multiple generic manufacturers produce vidarabine ophthalmic ointment.
• Labeling: Current FDA labeling primarily focuses on its use in herpes simplex keratitis.

Europe

• European Medicines Agency (EMA): Vidarabine has historically been available in European markets, often as a compounded preparation or through national drug registration processes.
• Market Dynamics: Similar to the U.S., its use has declined in favor of newer agents. Availability may vary by country.

Other Markets

• Vidarabine is approved and available in various other countries, particularly in regions where cost considerations are a significant factor in drug selection.

What are the Fundamental Economic Drivers and Constraints for Vidarabine?

The economic viability of vidarabine is primarily shaped by its generic status, therapeutic niche, and the availability of superior alternatives.

Economic Drivers

• Cost-Effectiveness: In its approved indications, particularly for ophthalmic use, generic vidarabine can offer a cost-effective treatment option compared to newer or branded antivirals. This is a key driver for its continued use in budget-constrained healthcare systems or for patients with limited insurance coverage.
• Established Efficacy: For its core indications, its efficacy is well-documented, providing a degree of market stability.
• Specialty Use: Its continued use in specific ophthalmic applications ensures a persistent, albeit small, demand.

Economic Constraints

• Genericization: The expiration of primary patents has resulted in intense price competition from generic manufacturers, limiting profit margins for any remaining branded producers and suppressing overall market value.
• Competition from Newer Agents: Acyclovir, valacyclovir, and others offer superior pharmacokinetic profiles, broader spectrums of activity for certain conditions, and often better patient convenience (e.g., oral administration vs. topical). This has significantly eroded vidarabine's market share in systemic treatments.
• Limited R&D Investment: The lack of patent protection and the mature nature of the drug discourage substantial R&D investment for new indications or advanced formulations.
• Toxicity and Side Effects: While generally considered safe in its approved applications, vidarabine can cause local irritation and has a less favorable systemic safety profile compared to newer agents, limiting its use in more severe or systemic infections.

What are the Potential Investment Scenarios and Risks for Vidarabine?

Investing in vidarabine presents a low-growth, high-competition scenario, primarily centered on niche markets and generic manufacturing.

Investment Scenarios

1. Generic Manufacturing Investment:

   • Focus: Establishing or acquiring manufacturing capabilities for generic vidarabine ophthalmic ointment.
   • Target Market: Primarily developing economies or segments within developed markets where cost is a primary determinant.
   • Profitability: Driven by high-volume sales and efficient, low-cost production. Margins will be thin, requiring scale.
   • Risk: Intense price wars among generic manufacturers, supply chain disruptions, and regulatory compliance costs.

2. Specialty Ophthalmic Market Play:

   • Focus: Maintaining or acquiring existing market share for a vidarabine-based ophthalmic product, potentially through optimized distribution channels or customer service.
   • Target Market: Existing prescribing patterns for herpes simplex keratitis in developed markets.
   • Profitability: Stable but low revenue streams. Profitability depends on minimizing operational costs and leveraging existing brand recognition or formulary acceptance.
   • Risk: Erosion of market share by competing topical treatments (e.g., trifluridine), changes in prescribing guidelines, and potential obsolescence if more effective treatments emerge.

3. Acquisition of Mature Product Portfolio:

   • Focus: Acquiring a small portfolio of generic antivirals including vidarabine from a company divesting non-core assets.
   • Target Market: Broad, leveraging existing regulatory approvals and manufacturing.
   • Profitability: Achieved through cost synergies and efficient management of a portfolio of established generics.
   • Risk: Integration challenges, continued pressure on margins across the portfolio, and regulatory hurdles for manufacturing transfers.

Key Investment Risks

• Intensified Generic Competition: Price erosion is a constant threat, impacting profitability even for established generic producers.
• Obsolescence: The development of new, more effective, or safer antiviral treatments could render vidarabine obsolete in its current indications.
• Regulatory Scrutiny: Manufacturing facilities and quality control are subject to stringent regulatory oversight. Non-compliance can lead to significant penalties and market withdrawal.
• Supply Chain Vulnerability: Reliance on raw material suppliers and global logistics can create vulnerabilities.
• Limited Growth Potential: The fundamental market dynamics of vidarabine preclude significant organic growth without substantial new R&D, which is unlikely given its product lifecycle.
• Interchangeability and Formulary Changes: Healthcare payers and pharmacy benefit managers can shift preferred agents, impacting market access and sales volumes.

What is the Outlook for Vidarabine?

The outlook for vidarabine is one of sustained, albeit limited, relevance in its established niche. It is not positioned for growth but rather for stable demand in specific therapeutic areas.

Market Outlook

• Ophthalmic Niche: Vidarabine ophthalmic ointment will likely maintain its position as a cost-effective option for herpes simplex keratitis, particularly in markets sensitive to price. The market size for this indication is relatively stable but small.
• Systemic Use Decline: Vidarabine's role in treating systemic viral infections is negligible and unlikely to recover due to the superiority of newer antivirals.
• Generic Market Dominance: The market will continue to be dominated by generic manufacturers. Profitability will hinge on operational efficiency and scale.
• No Significant Innovation Expected: Given the drug's age, lack of patent protection, and the availability of superior alternatives, significant R&D investment leading to new indications or groundbreaking formulations is improbable.

The investment thesis for vidarabine is therefore focused on efficient generic manufacturing and distribution within a defined, low-growth market segment.

---

Key Takeaways

• Vidarabine is an established antiviral primarily used topically for ocular herpes simplex infections.
• Original patents have long expired, leading to a highly competitive generic market with low profit margins.
• Newer antivirals like acyclovir and valacyclovir have largely replaced vidarabine in systemic treatments due to superior efficacy, safety, and pharmacokinetic profiles.
• The primary economic driver is its cost-effectiveness as a generic option in specific indications.
• Investment opportunities are limited to efficient generic manufacturing or niche specialty market plays, with inherent risks from intense competition and potential obsolescence.
• The outlook is for continued niche relevance without significant growth prospects.

---

Frequently Asked Questions

1. What is the primary therapeutic indication for which vidarabine is still widely prescribed? Vidarabine is still prescribed for herpes simplex keratitis, an infection of the cornea.

2. Which newer antiviral drugs have significantly impacted vidarabine's market share? Acyclovir and valacyclovir have significantly impacted vidarabine's market share, particularly in systemic treatments for herpes simplex and varicella-zoster virus infections.

3. Are there any significant patent protections currently in place for vidarabine that would grant market exclusivity? No, the foundational patents covering vidarabine's composition of matter and initial therapeutic uses have expired, leading to generic market entry.

4. What are the main economic challenges facing vidarabine manufacturers? The main economic challenges are intense price competition from generic manufacturers and the limited profit margins associated with a mature, off-patent drug.

5. Does vidarabine have any potential for new drug development or expanded therapeutic uses? While theoretically possible, significant R&D investment for new indications or formulations of vidarabine is unlikely due to its age, lack of patent protection, and the availability of more advanced therapeutic options.

---

Citations

[1] U.S. Food & Drug Administration. (n.d.). FDA Approved Drugs. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals (General source for FDA drug approvals, specific vidarabine approval data accessed through historical searches and drug databases).

[2] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from https://www.ema.europa.eu/en/medicines/human/referral/vidarabine-various-medicinal-products (Information on EMA's review processes and historical availability in Europe).

[3] Clinical Pharmacology [Database]. (n.d.). Vidarabine. Tampa, FL: Elsevier. (Access typically requires subscription, used for detailed pharmacological and clinical data).

[4] Lexicomp [Database]. (n.d.). Vidarabine. Hudson, Ohio: Lexicomp. (Access typically requires subscription, used for detailed pharmacological and clinical data).

[5] U.S. Patent and Trademark Office. (n.d.). Patents Database. Retrieved from https://www.uspto.gov/patents (General source for patent searches; historical patent data for vidarabine accessed through this database).